TELA - TELA Bio, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

TELA Bio, Inc.

1 Great Valley Parkway
Suite 24
Malvern, PA 19355
United States
484-320-2930
http://www.telabio.com

SectorHealthcare
IndustryMedical Devices
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Antony KoblishCo-founder, Pres, CEO & Director539.06kN/A1966
Dr. Maarten PersenaireCo-Founder & Chief Medical Officer402.5kN/A1957
Dr. E. Skott Greenhalgh Ph.D.Chief Technology Officer395.31kN/A1967
Ms. Nora E. BrennanChief Financial OfficerN/AN/A1968
Mr. Michael LeonardVP of OperationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

TELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. It offers reinforced tissue matrix products for a variety of reconstruction procedures, including hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery. The company provides a portfolio of OviTex Reinforced Tissue Matrix or OviTex products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix or OviTex PRS products to address the unmet needs in plastic and reconstructive surgery. It markets its products through a single direct sales force, principally in the United States. The company was founded in 2012 and is headquartered in Malvern, Pennsylvania.

Corporate Governance

TELA Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.